Insightec has announced a successful $150 million equity financing to further support the company's development and commercialization of MR-guided high intensity focused ultrasound (HIFU) technology.

Insightec’s proprietary technology, with over 160 systems installed globally, has been utilized in nearly 20,000 commercial applications. The technology is FDA approved for incisionless, immediate treatment of essential tremor and Parkinson’s disease. Earlier this year, Insightec unveiled a new version of its flagship platform, Exablate Neuro, dubbing it Exablate Prime, which offers a new user interface and improved ability to treat essential tremor and other movement disorders.

The investment was led by Fidelity Management & Research Company, with significant contributions from Nexus Neurotech Ventures and Ally Bridge Group. Additional support came from new investors Baillie Gifford, Catalio Capital Management, Fayez Sarofim & Co., and Gilmartin Capital, alongside strong backing from existing investors including affiliates of York Global Finance / Community Fund and Perceptive Advisors.
“We are grateful for the strong support of our mission from these new and existing investors,” said Maurice R Ferré, M.D., CEO and chairman of the board of Insightec. “This financing provides Insightec with runway to expand incisionless neurosurgery to the many patients suffering from movement disorders and continue to make calculated and strategic investments in new indications.”

Headquartered in Haifa, Israel, and Miami, Insightec also has offices in Dallas, Shanghai, and Tokyo. The company is currently exploring additional applications for focused ultrasound in neuroscience in collaboration with leading academic and medical institutions.

Researchers at Children’s National Hospital in Washington, D.C., have launched a pioneering clinical trial to assess the safety and potential therapeutic effects of HIFU for treating cerebral palsy symptoms.

Focused Ultrasound Homepage